Comparison of surveillance circulating tumor DNA and Merkel polyomavirus antibody titer for detection of Merkel cell carcinoma recurrence
Chan et al. ASCO 2025
Read More
Poster
The resources in this stream include various studies in cfDNA and ctDNA.
-
-
Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy may predict clinical outcomes in advanced stage melanoma: a multicente
Burkey et al. ASCO 2025
Read More
-
Circulating tumor DNA monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab plus chemotherapy with or withou
Lee J-Y, Ibañez C; Bidzinski M, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Feasibility of adjuvant therapy guided by circulating tumor DNA-based molecular residual disease (ctDNA-MRD) for stage II-III gastric cancer
Liu L, Li S, Qu H, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer
Abdelrahim M, Esmail A, Tin A, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Early treatment ctDNA dynamics to predict response to chemotherapy in patients with metastatic pancreatic cancer: a prospective, observation
Lee JY, Sidiqi B, Battaglia J, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer
Malla M, Aushev VN, Ramu A, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Exome analysis of over 5000 esophagogastric cancers
Mukherji R, Aushev VN, Rivero-Hinojosa S, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage
Montagut M, Tamberi S, Leone F, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA
Shen JPYC, Reiter JR, Babiarz J, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Impact of Perioperative Complications on MRD Detection and Prognosis Using ctDNA: Insights from the GALAXY Study
Oki E, Sato S, Ando K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation
Bercz A, Alvarez J, Kostrzewa CE, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma
Zhou M, Nam Bui N, Pan M, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Early on-treatment ctDNA dynamics and response by imaging in patients with sarcoma
Victor A. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Circulating tumor DNA monitoring in patients with advanced urothelial carcinoma treated with Enfortumab Vedotin +/- Pembrolizumab
Reyes KR, Jindal T, Mitchell B, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Association of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC)
Ayanambakkam A, Laliotis G, Reyes K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
Powles T, van der Heijden MS, Wang Y, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
EORTC2129-BCG: elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (Treat ctDNA trial).
Ignatiadis M, Saloustros E, Joaquim A, et al. ASCO Annual Meeting 2025, Chicago, IL. M
Read More
-
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant lasofoxifene in molecularly selected patients with hormone receptor positive (HR+)/HE
Wei M, Elias AD, Giridhar K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Circulating tumor DNA in patients with stage 2/3 HR+HER2-negative breast cancer receiving neoadjuvant endocrine therapy in the I-SPY2 Endocr
Alkhafaji S, Magbanua MJM, van ‘t Veer L, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Loading More...
